Psoriatic Arthritis News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

High Coronary Plaque Burden Is Independent of Metabolic Syndrome in Psoriatic Arthritis - Rheumatology Advisor



Rheumatology Advisor
 
High Coronary Plaque Burden Is Independent of Metabolic Syndrome in Psoriatic Arthritis 
Rheumatology Advisor
Patients with PsA without symptoms or a diagnosis of coronary artery disease have a higher burden of coronary plaque, which is independent of metabolic syndrome. Patients with well-established psoriatic arthritis (PsA) without any symptoms or a ...

 


How Cosentyx Resolves Enthesitis in Psoriatic Arthritis Patients ... - Market Realist



Market Realist
 
How Cosentyx Resolves Enthesitis in Psoriatic Arthritis Patients ... 
Market Realist
On November 14, 2016, Novartis (NVS) announced positive results from the Phase 3 pivotal study, FUTURE 1. This study highlighted the efficacy of Cosentyx in providing sustained benefit over three years in psoriatic arthritis patients. The drug works by ...

and more » 


Psoriatic arthritis explained - Pocono Record



Pocono Record
 
Psoriatic arthritis explained 
Pocono Record
Q: I have psoriasis but lately, I've notice some pain in my joints. I'm worried I could be developing psoriatic arthritis like my father did at my age. Is there a connection between psoriasis and psoriatic arthritis and is it hereditary? A: In short ...

 


Johnson & Johnson's Simponi Could See Steady Growth in 2018 - Market Realist



Market Realist
 
Johnson & Johnson's Simponi Could See Steady Growth in 2018 
Market Realist
In October 2017, the FDA approved Simponi Aria (golimumab) for the treatment of adult individuals with active psoriatic arthritis or active ankylosing spondylitis. Johnson & Johnson conducted the pivotal Phase 3 GO-VIBRANT trial to evaluate the safety ...

and more » 


Psoriatic Arthritis Drug Market Growth Opportunities, Industry Analysis, Size, Share, Geographic Segmentation ... - Facts of Week



Psoriatic Arthritis Drug Market Growth Opportunities, Industry Analysis, Size, Share, Geographic Segmentation ... 
Facts of Week
The key facts related to Psoriatic Arthritis Drug Industry, like product definition, cost, variety of applications, demand and supply are covered in this report. Competitive Analysis of the major Market Manufacturers will help all the market players in ...

 


Efficacy of Apremilast Monotherapy Assessed in Biologic-Naive Psoriatic Arthritis - Rheumatology Advisor



Rheumatology Advisor
 
Efficacy of Apremilast Monotherapy Assessed in Biologic-Naive Psoriatic Arthritis 
Rheumatology Advisor
Patients with psoriatic arthritis (PsA) who were taking and were na´ve to biologic medications experienced symptom relief with apremilast as early as 2 weeks into therapy, with sustained clinical improvement through 1 year of treatment, according to ...

 


Psoriatic arthritis rates increasing in Taiwan despite psoriasis plateau - Healio



Psoriatic arthritis rates increasing in Taiwan despite psoriasis plateau 
Healio
Prevalence and incidence rates of psoriatic arthritis increased significantly in Taiwan from 2000 to 2013, while psoriasis exhibited no substantial change in incidence, according to findings published in the Journal of Rheumatology. The researchers ...

 


New device for low-cost single-cell analysis identifies fibroblast subtypes in rheumatoid arthritis patients - Science Daily



Science Daily
 
New device for low-cost single-cell analysis identifies fibroblast subtypes in rheumatoid arthritis patients 
Science Daily
Moving forward, the researchers are compiling data from additional RA patients, and aim to obtain patient samples from other arthritic conditions such as psoriatic arthritis and osteoarthritis. In addition, they plan to use CITE-seq, a technique also ...

and more » 


Efficacy and Safety of Ixekizumab Evaluated in Active Psoriatic Arthritis - Rheumatology Advisor



Rheumatology Advisor
 
Efficacy and Safety of Ixekizumab Evaluated in Active Psoriatic Arthritis 
Rheumatology Advisor
Treatment with ixekizumab every 2 or 4 weeks in patients with active psoriatic arthritis demonstrated sustained efficacy and a favorable safety profile. In an extension period of the phase 3 SPIRIT-P1 study (ClinicalTrials.gov identifier: NCT01695239 ...

 


Lilly wins EU approval for psoriatic arthritis mAb - BioPharma-Reporter.com



BioPharma-Reporter.com
 
Lilly wins EU approval for psoriatic arthritis mAb 
BioPharma-Reporter.com
Eli Lilly's arthritis monoclonal antibody Taltz (ixekizumab) has been approved for a second indication in Europe. The European Commission (EC) granted marketing authorisation (MA) for Lilly's biologic Taltz last week as a treatment for active psoriatic ...